Your browser doesn't support javascript.
Efficacy and safety of azithromycin in Covid-19 patients: A systematic review and meta-analysis of randomized clinical trials.
Kamel, Ahmed M; Monem, Mona S A; Sharaf, Nour A; Magdy, Nada; Farid, Samar F.
  • Kamel AM; Department of Clinical Pharmacy, College of Pharmacy, Cairo University, Cairo, Egypt.
  • Monem MSA; Department of Clinical Pharmacy, College of Pharmacy, Cairo University, Cairo, Egypt.
  • Sharaf NA; Department of Clinical Pharmacy, College of Pharmacy, Cairo University, Cairo, Egypt.
  • Magdy N; Department of Clinical Pharmacy, College of Pharmacy, Cairo University, Cairo, Egypt.
  • Farid SF; Department of Clinical Pharmacy, College of Pharmacy, Cairo University, Cairo, Egypt.
Rev Med Virol ; 32(1): e2258, 2022 01.
Article in English | MEDLINE | ID: covidwho-1252046
ABSTRACT
Azithromycin (AZM) is commonly used in Covid-19 patients based on low-quality evidence, increasing the risk of developing adverse events and antimicrobial resistance. The current systematic review and meta-analysis investigated the safety and efficacy of AZM in treating Covid-19 patients using published randomized controlled trials. Google Scholar, PubMed, Scopus, Cochrane Library, Clinical Trials.gov, MEDLINE, bioRxiv and medRxiv were searched for relevant studies. The random-effects model was used to pool estimates using the Paule-Mandel estimate for heterogeneity. The odds ratio and raw difference in medians were used for dichotomous and continuous outcomes, respectively. The analysis included seven studies with 8822 patients (median age, 55.8 years; 61% males). The risk of bias was assessed as 'low' for five of the seven mortality results and as 'some concerns' and 'high' in one trial each. There were 657/3100 (21.2%) and 1244/5654 (22%) deaths among patients randomized to AZM and standard of care, respectively. The use of AZM was not associated with mortality in Covid-19 patients (OR = 0.96, 95% CI 0.88-1.05, p = 0.317 based on the random-effect meta-analysis). The use of AZM was not associated with need for invasive mechanical ventilation (OR = 0.96, 95% CI 0.49-1.87, p = 0.85) and length of stay (Δ = 1.11, 95% CI -2.08 to 4.31, p = 0.49). The results show that using AZM as routine therapy in Covid-19 patients is not justified due to lack of efficacy and potential risk of bacterial resistance that is not met by an increased clinical benefit.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Azithromycin / COVID-19 Drug Treatment / Anti-Bacterial Agents Type of study: Diagnostic study / Experimental Studies / Prognostic study / Randomized controlled trials / Reviews / Systematic review/Meta Analysis Limits: Humans / Middle aged Language: English Journal: Rev Med Virol Journal subject: Virology Year: 2022 Document Type: Article Affiliation country: Rmv.2258

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Azithromycin / COVID-19 Drug Treatment / Anti-Bacterial Agents Type of study: Diagnostic study / Experimental Studies / Prognostic study / Randomized controlled trials / Reviews / Systematic review/Meta Analysis Limits: Humans / Middle aged Language: English Journal: Rev Med Virol Journal subject: Virology Year: 2022 Document Type: Article Affiliation country: Rmv.2258